Newsroom: Latest News
Here is the new Press Release Title
Nouzilly, June 28, 2024 – Meet Igyxos at ESHRE2024 in Amsterdam !
Igyxos will present two posters (P-081 and P-654) at ESHRE2024 in Amsterdam (7-10 july 2024).
Marie-Christine Maurel and Elodie Kara will be there to discuss preclinical data underlying how our first-in-class monoclonal antibody IGX12 can address unmet need for male fertility, and improve the efficacy of female infertility treatments.
More information on ESHRE2024 here: https://www.eshre.eu/ESHRE2024/
​
​
About Igyxos
Igyxos’ mission is to develop new and innovative medical and pharmaceutical technologies in the field of human fertility. Igyxos is involved in all phases of development, from the discovery of promising targets to the identification of potential active compounds such as antibodies. The success of its €7.5 million Series A funding led by Bpifrance, through the FABS funds, alongside with Go Capital Amorçage II and Loire Valley Invest Funds managed by Go Capital and the Emergence Innovation II Fund managed by Sofimac Innovation, will allow Igyxos to develop its lead compound and reach clinical proof of concept. www.igyxos.com.
​
Press Contacts:
Igyxos
Elodie Kara